Mark R. Lackner

<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd et al. · Clinical Cancer Research · 2009 · 473 citations

Medicine, Oncology, Pharmacology +17

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu et al. · Clinical Cancer Research · 2012 · 417 citations

Medicine, Nuclear Medicine, Oncology +17

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 360 citations · Full text

Medicine, Oncology, Pharmacology +15

TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer

Susanna Stinson, Mark R. Lackner, Alex Adai et al. · Science Signaling · 2011 · 314 citations

Life Sciences, Molecular Biology, Oncology +17

Molecular Biomarker Analyses Using Circulating Tumor Cells

Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke et al. · PLoS ONE · 2010 · 297 citations · Full text

Medicine, Cell Biology, Oncology +17